Fertility outcome following combined methotrexate treatment of unruptured extrauterine pregnancy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 10826577.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess the effectiveness of systemic treatment with methotrexate in combination with local injection for unruptured tubal pregnancy, and to evaluate reproductive function following treatment. Prospective, open clinical study. University clinic. Sixty-seven women with unruptured tubal pregnancy. Systemic methotrexate (intramuscular methotrexate 0.5 mg/kg for up to five days) in combination with local application of 12.5 mg methotrexate via laparoscopy. The subsequent surgical intervention required and future fertility. In 89.6% of women no further surgical intervention was required and 47 women (81%) experienced subsequently an intrauterine pregnancy. In 39 of 40 women who underwent hysterosalpingography following treatment, patency of the affected tube was observed. Combined local and systemic methotrexate treatment for unruptured tubal pregnancy seems to be more effective than each therapeutic modality alone.
Medical subject headings
- Abortifacient Agents, Nonsteroidal
- Fertility
- Methotrexate
- Pregnancy, Tubal